S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.42 (+0.90%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
NVDA   196.11 (+2.95%)
BABA   173.52 (+2.60%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
NFLX   278.05 (+1.00%)
GILD   65.22 (+0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.42 (+0.90%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
NVDA   196.11 (+2.95%)
BABA   173.52 (+2.60%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
NFLX   278.05 (+1.00%)
GILD   65.22 (+0.48%)
Log in

Obseva Stock Price, News & Analysis (NASDAQ:OBSV)

$7.52
+0.03 (+0.40 %)
(As of 10/21/2019 04:00 PM ET)
Today's Range
$7.40
Now: $7.52
$7.78
50-Day Range
$7.37
MA: $8.70
$9.90
52-Week Range
$7.14
Now: $7.52
$17.87
Volume31,209 shs
Average Volume46,205 shs
Market Capitalization$341.99 million
P/E RatioN/A
Dividend YieldN/A
Beta0.84
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OBSV
CUSIPN/A
Phone41-22-552-3840

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.23 per share

Profitability

Net Income$-76,720,000.00

Miscellaneous

Employees43
Market Cap$341.99 million
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable

Receive OBSV News and Ratings via Email

Sign-up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter.


Obseva (NASDAQ:OBSV) Frequently Asked Questions

What is Obseva's stock symbol?

Obseva trades on the NASDAQ under the ticker symbol "OBSV."

How were Obseva's earnings last quarter?

Obseva SA (NASDAQ:OBSV) announced its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.58) by $0.22. View Obseva's Earnings History.

When is Obseva's next earnings date?

Obseva is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Obseva.

What price target have analysts set for OBSV?

4 brokers have issued twelve-month price objectives for Obseva's shares. Their forecasts range from $16.00 to $44.00. On average, they expect Obseva's share price to reach $32.67 in the next year. This suggests a possible upside of 334.4% from the stock's current price. View Analyst Price Targets for Obseva.

What is the consensus analysts' recommendation for Obseva?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obseva in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Obseva.

What are Wall Street analysts saying about Obseva stock?

Here are some recent quotes from research analysts about Obseva stock:
  • 1. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our risk-adjusted net present value (rNPV) approach ascribes $1.9B to linzagolix (formerly to nolasiban. We utilize an 85% probability of approval for linzagolix and 75% for nolasiban." (9/4/2019)
  • 2. According to Zacks Investment Research, "ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. " (7/31/2019)

Has Obseva been receiving favorable news coverage?

Headlines about OBSV stock have trended somewhat positive recently, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Obseva earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Obseva.

Are investors shorting Obseva?

Obseva saw a decrease in short interest in September. As of September 30th, there was short interest totalling 290,800 shares, a decrease of 33.4% from the August 30th total of 436,900 shares. Based on an average daily trading volume, of 44,400 shares, the short-interest ratio is presently 6.5 days. Currently, 1.5% of the company's shares are sold short. View Obseva's Current Options Chain.

Who are some of Obseva's key competitors?

What other stocks do shareholders of Obseva own?

Who are Obseva's key executives?

Obseva's management team includes the folowing people:
  • Dr. Ernest Loumaye, Co-Founder, CEO & Director (Age 67)
  • Mr. Timothy M. Adams, Chief Financial Officer (Age 59)
  • Dr. Jean-Pierre Gotteland Ph.D., Chief Scientific Officer and Head of R&D (Age 54)
  • Mr. Mario Vincent Corso, Sr. Director of Investor Relations
  • Dr. Elke Bestel M.D., Chief Medical Officer & Head of Pharmacovigilance (Age 53)

When did Obseva IPO?

(OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

Who are Obseva's major shareholders?

Obseva's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Wedbush Securities Inc. (0.09%).

Which major investors are buying Obseva stock?

OBSV stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..

How do I buy shares of Obseva?

Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Obseva's stock price today?

One share of OBSV stock can currently be purchased for approximately $7.52.

How big of a company is Obseva?

Obseva has a market capitalization of $341.99 million. The company earns $-76,720,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Obseva employs 43 workers across the globe.View Additional Information About Obseva.

What is Obseva's official website?

The official website for Obseva is http://www.obseva.com/.

How can I contact Obseva?

Obseva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-22-552-3840 or via email at [email protected]


MarketBeat Community Rating for Obseva (NASDAQ OBSV)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  229 (Vote Outperform)
Underperform Votes:  221 (Vote Underperform)
Total Votes:  450
MarketBeat's community ratings are surveys of what our community members think about Obseva and other stocks. Vote "Outperform" if you believe OBSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBSV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel